SMARCA4 encodes the central ATPase subunit of SWI/SNF chr19 remodeling complexes, functioning as a critical regulator of gene expression through ATP-dependent chr19 restructuring 1. The protein modulates nucleosome topology to enable transcriptional activation and repression, serving as both a tumor suppressor and developmental regulator 21. SMARCA4 is aberrantly expressed in approximately 5-10% of human malignancies, with particularly high frequencies in non-small cell lung cancer (NSCLC), where alterations are associated with poor prognosis and reduced chemotherapy response 23. Loss-of-function mutations (Class I) lead to tumor suppressor inactivation, while missense mutations (Class II) can have dominant-negative effects 1. SMARCA4-deficient tumors, including thoracic undifferentiated tumors and small cell carcinoma of the ovary hypercalcemic type, represent distinct aggressive entities with unique clinicopathological features 45. Germline variants cause hereditary conditions including rhabdoid tumor predisposition syndrome-2 and Coffin-Siris syndrome 1. Therapeutically, SMARCA4 alterations predict resistance to conventional therapies but may respond to immune checkpoint inhibitors and targeted approaches including synthetic lethal strategies 167.